Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a/1b, Open-Label, Multicenter Study Evaluating the Safety and Feasibility of ITIL-306 in Subjects With Advanced Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase 1a/1b, Open-Label, Multicenter Study Evaluating the Safety and Feasibility of ITIL-306 in Subjects With Advanced Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ITIL-306 (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Adenocarcinoma; Carcinoma; Endometrial cancer; Fallopian tube cancer; Lung cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man
  • Sponsors Instil Bio

    • Most Recent Events

    • 22 Feb 2023 Status changed from recruiting to active, no longer recruiting.
    • 31 Jan 2023 According to an Instil Bio media release, Instil is consolidating manufacturing and Phase 1 clinical trial of CoStAR-TIL to its operations in Manchester, U.K.
    • 09 Jan 2023 According to an Instil Bio media release, the company expects to release initial safety, translational, and efficacy data from dose escalation cohorts at a medical conference in 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top